SAVA - Cassava Sciences Appoints Three New Members to its Board of Directors | Benzinga
AUSTIN, Texas, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced the appointment of three new members to its Board of Directors, effective immediately.
Claude Nicaise, MD – Dr. Nicaise has held clinical/regulatory leadership roles that have resulted in 14 new drug approvals in various diseases areas, including neuroscience. Dr. Nicaise was a Senior Vice President of Strategic Development and Global Regulatory Affairs at Alexion Pharmaceuticals from 2008 to 2014. From 1983 to 2008, Dr. Nicaise served in various positions of increasing responsibility at Bristol-Myers Squibb, including senior positions such as Vice President of Global Development and Vice-President of Worldwide Regulatory Science and Strategy.
Pierre Gravier, MS – In July 2023, Mr. ...